-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Maplirpacept in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Maplirpacept in Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Maplirpacept in Lymphoma Drug Details: Maplirpacept (TTI-622) is under development for the...
-
Product Insights
Focal Segmental Glomerulosclerosis (FSGS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Focal Segmental Glomerulosclerosis (FSGS) - Drugs In Development, 2023’, provides an overview of the Focal Segmental Glomerulosclerosis (FSGS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Focal Segmental Glomerulosclerosis (FSGS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Glomerulonephritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Glomerulonephritis - Drugs In Development, 2023’, provides an overview of the Glomerulonephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Systemic Sclerosis (Scleroderma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Systemic Sclerosis (Scleroderma) - Drugs In Development, 2023’, provides an overview of the Systemic Sclerosis (Scleroderma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Kidney Disease (Chronic Renal Failure) - Drugs In Development, 2023’, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Glaucoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Glaucoma - Drugs In Development, 2023’, provides an overview of the Glaucoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Interstitial Lung Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Interstitial Lung Fibrosis - Drugs In Development, 2023’, provides an overview of the Interstitial Lung Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Interstitial Lung Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Sector Analysis
United Kingdom (UK) Forecourt Market Size and Forecast by Segment and Fuel Retailer Profiles to 2027
UK Forecourt Market Report Overview The total forecourt sales in the UK was GBP66.96 billion in 2022 and the market is expected to record a CAGR of more than 1% during 2023-2027. Customer demand for convenience is driving the forecourt product and service offerings by fuel companies. UK Forecourt Market Outlook, 2022-2027 (GBP Billion) Buy the Full Report for Additional Insights on the UK Forecourt Market Forecast Download a Free Sample Report The UK Forecourt market research report is invaluable...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMS-986104 in Rheumatoid Arthritis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BMS-986104 in Rheumatoid Arthritis Drug Details: BMS-986104 is under development for the treatment of atopic...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – FT-011 in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FT-011 in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FT-011 in Chronic Kidney Disease (Chronic Renal Failure)...